Skip to main content
News Icon

New Speaker and Executive Board Member

Prof. Joachim L. Schultze from the LIMES Institute Bonn resigned in his position as speaker and member of the executive board of the Cluster of Excellence.

We wish him all the best for his future tasks in the field of immunology and we are more then happy that he supports the Cluster of Excellence ImmunoSensation as a member of the steering committe and valuable group leader.

As a succesor for the speaker position Prof. Waldemar Kolanus and as succesor for the executive board member position Prof. Elvira Mass, both from the LIMES Institute in Bonn, will replace Prof. Joachim L. Schultze.

Welcome Prof. Kolanus and Prof. Mass in your new roles in the Cluster of Excellence ImmunoSensation2.

Related news

Pandyra Publication Graphical Abstract

Publication

Genetic mutation affects survival after viral infection

—Scientists discovered that haploinsufficiency in the Pax5 gene affects antiviral responses. The study was led by Prof. Dr. Aleksandra Pandyra from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn in collaboration with Prof. Dr. Arndt Borkhardt, Clinic Director at the Pediatric Oncology at the University Hospital Düsseldorf. The findings were published in the latest edition of EMBO Molecular Medicine.
View entry
Reckzeh News

Honors & Funding

Creating Personalized Cancer Treatments

—Bonn researchers aim to improve colon cancer treatment using 3D organoids and digital twins. Funded by the Federal Ministry of Education and Research (BMBF), a collaborative project involving the University of Bonn, the company ESQlabs and the University Hospital Bonn is seeking to refine the therapy recommendations given to colon cancer patients. To this end, “ISPOT-K” is merging organoids taken from patients with the power of digital twin technology.
View entry
AG Kürthen Multiple Sclerosis Bonn

Publication

Potential target for MS therapy discovered

—Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system caused by the immune system. B cells, which are a type of white blood cell, play a role in the development of MS and are thus a target for therapies. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the FAU Erlangen-Nuremberg identified the membrane protein MLC1 as a potential target antigen in MS. The results of the work have now been published in the renowned journal “Neurology Neuroimmunology & Neuroinflammation”.
View entry

Back to the news overview